CompletedNot applicableNCT01982123

SPECT/CT in Measuring Lung Function in Patients With Cancer Undergoing Radiation Therapy

This pilot clinical trial studies single photon emission computed tomography (SPECT)/computed tomography (CT) in measuring lung function in patients with cancer undergoing radiation therapy. Diagnostic procedures that measure lung function may help doctors find healthy lung tissue and allow them to plan better treatment.

Checked against the public recordLast updated Dec 13, 2018 · Source: ClinicalTrials.gov

StatusCompleted
PhaseNot applicable
U.S. locations2
SponsorUniversity of Washington
01
Study overview

What this study is about

Purpose
Diagnostic
Study type
Interventional
Phase
Not applicable
Sponsor
University of Washington
Interventions being studied
Diagnostic Test: SPECT/CT; Procedure: Single Photon Emission Computed Tomography; Radiation: Technetium Tc-99m Albumin Aggregated; Drug: Technetium Tc-99m DTPA
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach
03
Public criteria

Who may be able to participate

Inclusion Criteria: * Cancer patients receiving radiation treatment to the thorax to at least 45 Gy; patient must have pathologic confirmation of diagnosis, or have an enlarging lung mass on at least two scans spaced 3 months apart, and FDG avidity on PET scan * Patients must be planned for at least 45 Gy of thoracic radiation * Patients are not required to have measurable disease; post-operative patients (patients who have had surgical resection of the lung) are eligible * Patients must have pulmonary function as defined below: * Abnormal pulmonary function test within 3 months of study entry * Prior radiation to the lungs * Prior surgical resection of lung tissue (i.e. wedge resection, lobectomy, or pneumonectomy) * Clinical diagnosis of chronic obstructive pulmonary disease (COPD) or emphysema * Ongoing oxygen use * There are no limits on prior therapy; patients are allowed to have prior chemotherapy, radiation therapy, and surgery; patients are allowed to have concurrent chemotherapy with radiation treatment; patients are allowed to have chemotherapy after radiation treatment; patients are not allowed to have planned lung resection after radiation * Ability to understand and the willingness to sign a written informed consent document * Patients will typically be enrolled on this trial prior to beginning the radiation treatment course; however, if a patient has had a SPECT/CT 99mTc-MAA and 99mTc-DTPA scan as part of routine medical care within 6 weeks prior to initiation of radiation treatment, he/she is eligible for trial enrollment up to the last day of the radiation treatment course Exclusion Criteria: * Patients must not be planned for lung resection after radiation therapy * Patients receiving \< 45 Gy radiation * Patients who received radiation to the chest within the past 6 months * Patients unable to tolerate a SPECT/CT 99mTc-MAA and 99mTc-DTPA scan * Patients who are not planning to adhere to the required follow up schedule as outlined in this protocol * Pregnant women * Women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception * Patients unable to provide informed consent

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumSeattle, Washington
  • ProCure Proton Therapy Center-SeattleSeattle, Washington

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 13, 2018. Always confirm current availability with the study team.

View original record ↗